| Literature DB >> 32294470 |
Qimin Hu1, Lan Liu1, Li Zhou1, Haiyan Lu1, Jiayi Wang1, Xiangyan Chen2, Qiaoshu Wang3.
Abstract
Fluoxetine is one of the most promising drugs for improving clinical outcome in patients with ischemic stroke. This in vivo study investigated the hypothesis that fluoxetine may affect HIF-1α-Netrin/VEGF cascade, angiogenesis and neuroprotection using a rat model of transient middle cerebral artery occlusion (tMCAO). The rats were given fluoxetine or saline after tMCAO for 4 weeks. Then, protein expression of HIF-1α-Netrin/VEGF cascade was examined at 1, 2, 4 weeks after tMCAO. In vivo synchrotron radiation were performed to observe microangiography of ischemic brain after 4 weeks of tMCAO. The infarct size and neurobehavioral test were carried out 1 to 4 weeks after tMCAO. Results revealed that HIF-1α expression was upregulated in fluoxetine-treated group. Similarly, fluoxetine increased protein expression of Netrin and its receptor DCC, VEGF and its receptor VEGFR. Synchrotron radiation angiography revealed more branches in fluoxetine-treated rats. We found no difference of infarct volume between fluoxetine and saline treated rats after 1 week of tMCAO, and ischemia-induced brain atrophy volume in fluoxetine-treated group was attenuated after 4 weeks of tMCAO. Neurological deficits were improved in fluoxetine-treated rats at 3 and 4 weeks after tMCAO. Our results indicated that fluoxetine could upregulate protein expression of HIF-1α-Netrin/VEGF cascade, promote angiogenesis, and improve long-term functional recovery after ischemic stroke.Entities:
Keywords: Fluoxetine; Hypoxia-inducible factor-1α; Middle cerebral artery occlusion; Netrin-1; Vascular endothelial growth factor
Mesh:
Substances:
Year: 2020 PMID: 32294470 DOI: 10.1016/j.expneurol.2020.113312
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330